Pharma News
01 Feb 2026 to 07 Feb 2026
Feb 7, 2026
Ardelyx Patent Prolongs Tenapanor Brand's Strategic Outlook Until 2042
Ardelyx (NasdaqGM:ARDX) has received a new US patent for oral formulations of its drugs IBSRELA and XPHOZAH, extending exclusivity until 2042. This patent enhances intellectual property protection for Ardelyx's gastrointestinal and kidney therapies, potentially influencing its capital allocation and competitive strategy in a market with generics.
Feb 7, 2026
Are the prices of anti-obesity medications Ozempic, Wegovy, and Mounjaro decreasing?
GLP-1 drugs are increasingly central to obesity care in clinics from Dubai to New York, but their widespread uptake has led to challenges in pricing, supply, and regulation. In the US, this surge in use faces political scrutiny regarding affordability.
Feb 7, 2026
The death of a woman in Madurai sparks renewed demands for the regulation of health-related advertisements.
The death of a 19-year-old woman in Madurai has sparked renewed calls for stricter regulation of health advertisements, especially on social media. Advocates emphasize the need to curb misleading claims made by unqualified individuals, highlighting the potential dangers of unregulated health information.
Feb 7, 2026
Government Steps Up Efforts Against Fake Medications: More than 960 Inspections Conducted Based on Risk Factors Since ...
The Government of India has intensified its crackdown on counterfeit drugs, conducting over 960 risk-based inspections since December 2022 and resulting in 3,056 prosecutions since FY 2020-21. The initiative aims to combat substandard, spurious, and adulterated drugs, ensuring public safety and regulatory compliance in the pharmaceutical sector.
Feb 7, 2026
Government informs Lok Sabha that 172 human medications and 39 veterinary drugs have been prohibited over the past three years.
The Central Drugs Standard Control Organisation (CDSCO) has banned 172 drugs for human use and 39 for animal use over the past three years, as announced by Jagat Prakash Nadda in the Lok Sabha. The bans include various Fixed Dose Combinations (FDCs) to ensure public safety.
Feb 7, 2026
India Highlights Challenges in Standardizing Nutraceuticals Due to Overlapping Vitamin Regulations
India's government has identified major challenges in standardizing nutraceuticals due to overlapping vitamin classifications and varying global definitions. This complexity complicates the regulation of health supplements, impacting the industry’s growth and consumer safety.
Feb 7, 2026
J&K Health Minister announces that a bill addressing drug abuse will be presented during the current assembly session.
Jammu and Kashmir's Health Minister Sakina Itoo announced that a bill addressing drug abuse will be presented in the current legislative assembly session. The initiative aims to tackle the growing issue of drug abuse in the region.
Feb 6, 2026
Novo Nordisk Stock Recovers Following FDA Action on Unauthorized Drug Copies - TradingView
Shares of Novo Nordisk A/S rose 4.7% after the FDA announced it would target companies marketing unapproved versions of drugs, including cheaper alternatives to its weight-loss drug Wegovy. This follows a recent sell-off due to Hims & Hers Health Inc. introducing a $49 compounded version of Wegovy, which pressured Novo's stock earlier in the week.
Feb 6, 2026
Bayer Unveils Findings That May Position Stroke Prevention Medication as Its Next Major Success
Bayer's experimental drug asundexian has shown a 26% reduction in the risk of secondary strokes in a Phase 3 trial, supporting its potential as a new treatment option. The study, OCEANIC-STROKE, involved over 12,000 participants and demonstrated no increase in major bleeding risk. Asundexian could become the first approved drug for secondary stroke prevention, with blockbuster potential, amid competition from other Factor XI inhibitors.
Feb 6, 2026
President Trump Introduces TrumpRx, Vowing Reduced Medication Costs: Is It Genuine? - Decrypt
The TrumpRx.gov platform launched to reduce U.S. prescription drug prices by offering discounts tied to international rates. It features over 40 branded drugs, including Ozempic and Wegovy, with discounts up to 93%. While supporters hail it as a significant healthcare intervention, critics argue it mainly benefits uninsured patients and question the sustainability of the discounts.
Feb 6, 2026
Uncovering Formycon AG: Is This Under-the-Radar Biotech Poised for a Breakthrough? - AD HOC NEWS
Formycon AG, a German biotech firm specializing in biosimilars, is gaining attention for its potential to disrupt the market as patents for blockbuster biologics expire. While not trending on social media, its focused approach and pipeline could yield significant returns for investors willing to navigate the complexities of the biosimilar landscape. The stock is traded under ISIN DE000A1EWVY8.
Feb 6, 2026
Trump administration introduces TrumpRx platform for affordable medications - KCRA
The Trump administration has launched TrumpRx, a website aimed at providing discounted prescription drugs directly to consumers, bypassing insurance middlemen. The site features over 40 medications, including obesity drugs like Ozempic and Wegovy, with prices significantly lower than typical costs. However, experts express skepticism about its benefits for insured individuals. Major pharmaceutical companies involved include Pfizer, AstraZeneca, and Eli Lilly.
Feb 6, 2026
An In-Depth Look at Biogen (BIIB): Transitioning from a Leader in MS to a Hub of Neuro-Innovation
Biogen Inc. (NASDAQ: BIIB) is undergoing a significant transformation under CEO Christopher Viehbacher, moving away from the Aduhelm controversy and focusing on neurodegenerative therapies. The company reported a strong Q4 2025 earnings beat, with adjusted EPS of $1.99. Key products include Leqembi for Alzheimer’s and Skyclarys for Friedreich’s Ataxia, as Biogen aims to stabilize its revenue amid competition from Eli Lilly and Roche.
Feb 6, 2026
Novo experiences initial decline in Ozempic sales within the Greater China area.
Novo Nordisk's diabetes drug Ozempic experienced its first sales decline in the greater China region, dropping 7% to approximately 5.4 billion Danish crowns ($853 million) in 2025. This downturn is attributed to increased competition from drugs like Eli Lilly's Mounjaro and Innovent Biologics' mazdutide, which have recently been approved for use in China.
Feb 6, 2026
(02/06/26) Best Selections for 2026: AbbVie Inc. (ABBV) - MoneyShow
AbbVie Inc. (ABBV) has successfully transitioned from declining Humira sales, which once accounted for 75% of revenue, to new immunology drugs Skyrizi and Rinvoq, generating $6.9 billion in recent quarterly sales. The company anticipates these drugs will reach $31 billion by 2027. AbbVie also boasts a strong pipeline with 20 drugs in phase III. The stock has risen over 20% in 2025.
Feb 6, 2026
FDA Chief Marty Makary Promises Quick Action Against Companies Engaging in Mass Marketing...
FDA Commissioner Dr. Marty Makary announced a crackdown on companies mass-marketing "illegal copycat drugs." The agency aims to swiftly address the issue to protect consumers and ensure compliance with drug regulations.
Feb 6, 2026
TrumpRx Launches with 43 Available Medications - NOTUS
President Donald Trump announced the launch of TrumpRx, a new government website aimed at reducing drug prices by acting as a middleman between pharmaceutical companies and consumers. Currently offering 43 medications, including GLP-1s, TrumpRx will provide coupons for discounted prices. Major companies like Pfizer, AstraZeneca, and Eli Lilly are involved, but the site won't sell drugs directly or accept health insurance.
Feb 6, 2026
Eli Lilly Diversifies Its Portfolio with Autoimmune Treatments, Gene-Editing Initiatives, and Expansion in the U.S.
Eli Lilly has partnered with Repertoire Immune Medicines to develop therapies for autoimmune diseases and with Seamless Therapeutics for gene editing treatments for hearing loss. The company plans to invest over $3.5 billion in a new Pennsylvania facility to enhance production of next-generation injectables, signaling a strategic shift beyond its current focus on GLP-1 obesity treatments.
Feb 6, 2026
Trump Introduces TrumpRx.gov to Offer Affordable Medication Prices, Reports DrugsControl Media Services
President Donald Trump has launched TrumpRx.gov, a new online platform aimed at providing significantly lower prescription drug prices for American consumers. The initiative was announced on February 5, 2026, as part of efforts to enhance affordability in the pharmaceutical market.
Feb 6, 2026
Novo faces new challenges in the Semaglutide patent dispute in India.
A judge has permitted antitrust claims against a major pharmaceutical company to proceed, ruling that it likely employed bundled rebates and patent abuse to maintain its insulin monopoly. However, one allegation was dismissed.
Feb 6, 2026
Authorities Strengthen Control Over Drug Operations Through Joint Raids and Arrests
Indian enforcement agencies, including the Special Investigation Teams (SIT) and the Enforcement Directorate (ED), have launched coordinated raids against drug networks in Uttar Pradesh, Punjab, Bihar, and Chhattisgarh. The operations have led to arrests and asset seizures, targeting illicit activities involving drugs like Tramadol and Codeine syrup.
Feb 6, 2026
Market for Generic Medications Expected to Hit USD 762.48 Billion - GlobeNewswire
The global generic drugs market is projected to grow from USD 491.67 billion in 2026 to nearly USD 762.48 billion by 2035, with a CAGR of 5%. North America led the market in 2025, driven by chronic disease prevalence and patent expirations. Key players include Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and Viatris.
Feb 6, 2026
Market Analysis and Forecast for Large Molecule Drug Substance CDMO: Size, Share, Trends, and Growth Projections for 2030
The large molecule drug substance CDMO market is expected to grow at a CAGR of 9%, driven by rising demand for biologics and biosimilars, advancements in bioprocessing, and increased FDA and EMA approvals. Key players include Eurofins Scientific, WuXi Biologics, and Boehringer Ingelheim. The shift towards biologics is reshaping the pharmaceutical landscape, enhancing treatment options for chronic diseases.
Feb 6, 2026
Novartis Expected to Experience Profit Decline in 2026 Due to Entresto Patent Expiration
Novartis forecasts a low single-digit decline in 2026 operating profit, impacted by patent expiries on key drugs like Entresto and Xolair. The company is relying on cancer drugs Kisqali and Scemblix, alongside a $30 billion investment in acquisitions, to drive growth. CEO Vas Narasimhan remains optimistic about mid-term targets despite recent share declines.
Feb 6, 2026
Analysis: Hims' $49 weight-loss medication shakes up investor confidence in the cash-pay obesity sector | WKZO
Hims & Hers has launched a $49 compounded version of Novo Nordisk's Wegovy, raising concerns in the obesity drug market. This move threatens Novo's sales and has led to a significant drop in its shares. Analysts question the legality and efficacy of Hims' pill, while Novo plans legal action to protect its interests.
Feb 6, 2026
Government Recognizes Difficulties in Implementing Restrictions on Unreasonable FDCs
Union Minister for Health and Family Welfare Jagat Prakash Nadda acknowledged the difficulties in enforcing bans on irrational Fixed Dose Combinations (FDCs) during a Lok Sabha session on February 6, 2026. The government is facing challenges in regulating these banned medicines effectively.
Feb 5, 2026
CDSCO releases preliminary guidelines for the online submission of import application requests for in...
The Central Drugs Standard Control Organisation (CDSCO) has issued a draft guidance document aimed at facilitating online submission of import license applications for in-vitro diagnostic (IVD) medical devices. This initiative is designed to streamline the import process for IVD medical device importers in India.
Feb 5, 2026
Shifts in the patent environment for Ozempic - Health Tech World
Novo Nordisk's drugs Ozempic and Wegovy, both containing semaglutide, face patent expirations in China, India, and Brazil in 2026, allowing generics to enter these markets. However, exclusivity will remain in Europe, the US, and Japan until 2031 due to patent extensions. Generics companies may pursue litigation and workarounds to navigate Novo Nordisk's extensive patent portfolio.
Feb 5, 2026
Resistance to the Approval of Generic or Biosimilar Medications by Cofepris
COFEPRIS has introduced a new mechanism in Mexico to allow patent holders to oppose marketing authorizations for generic or biosimilar drugs that may infringe on patent rights. This initiative aims to enhance the protection of active pharmaceutical ingredients (APIs) and improve collaboration with the Mexican Institute of Industrial Property (IMPI) to ensure thorough evaluations before granting approvals.
Feb 5, 2026
CVS Health will remove bone disease medications from Amgen and Lilly from certain drug lists - KFGO
CVS Health will replace Amgen's Prolia and Eli Lilly's Forteo with lower-cost alternatives in its preferred drug lists starting April 1. The changes include adding biosimilars like Ospomyv and Stoboclo, and generics such as Bonsity and Tymlos, potentially reducing costs by over 50%. CVS's strategy has already saved $1.5 billion for customers.
Feb 5, 2026
Hims & Hers introduces a version of the Wegovy pill, leading to legal warnings from the pharmaceutical company Novo Nordisk.
Hims & Hers announced the launch of a cheaper, off-brand version of the weight-loss pill Wegovy, produced by Novo Nordisk, which has threatened legal action against Hims for creating an "inauthentic" version of semaglutide. Hims plans to sell its compounded pill for $49 initially, undercutting Novo's price of $149. Shares of Novo Nordisk fell over 5% following the announcement.
Feb 5, 2026
2026 Forecast: Insights into the CDMO Market for Injectable Products - Analysis from DCAT Value Chain
In a recent podcast, Ian Tzeng of L.E.K. Consulting discussed the 2026 outlook for the CDMO market for injectables, highlighting key developments from 2025, including US tariff/trade policies, most-favored nation drug pricing, and emerging technology trends. The insights aim to inform stakeholders about the evolving landscape in the pharmaceutical contract services sector.
Feb 5, 2026
Trump Administration Introduces Direct-to-Consumer Prescription Drug Website - CNBC
President Trump announced the launch of TrumpRx, a direct-to-consumer website aimed at lowering prescription drug costs in the U.S. The platform connects patients to discounts from drugmakers like Eli Lilly and Novo Nordisk, particularly benefiting cash-paying patients. However, experts caution that insured individuals may not see significant savings compared to existing methods. The site features drugs from AstraZeneca, EMD Serono, and Pfizer as well.
Feb 5, 2026
President Trump introduces TrumpRx: Who stands to benefit from reduced medication expenses? - KCRA
The White House has launched Trump Rx, a website allowing Americans to purchase discounted prescription drugs directly from manufacturers, including Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. Notable medications like Zepbound and Wegovy will be available for $350, down from $1,000-$1,300. Experts caution that the platform may primarily benefit uninsured individuals, as purchases won't count toward insurance deductibles.
Feb 5, 2026
Lilly Rises on Leading Position in Obesity Treatment, Surpassing Novo Nordisk - Whalesbook
Eli Lilly & Co. forecasts a 27% sales growth, driven by its obesity drugs Mounjaro and Zepbound, contrasting with Novo Nordisk's projected 13% sales decline. Lilly's shares rose 8.3% following strong fourth-quarter results and extended patent protections. The company anticipates FDA approval for its oral weight-loss pill, orforglipron, enhancing its competitive edge in the obesity market.
Feb 5, 2026
CVS Health will remove bone disease medications from Amgen and Lilly from select drug lists.
CVS Health will replace Amgen's Prolia and Eli Lilly's Forteo with lower-cost alternatives in its preferred drug lists starting April 1. The pharmacy benefit management unit, Caremark, will add biosimilars like Ospomyv and Stoboclo, and generics such as Bonsity and Tymlos, aiming to reduce costs by over 50%. This strategy has already saved $1.5 billion for customers.
Feb 5, 2026
Novo Nordisk pledges to take legal measures to safeguard the Wegovy medication - France 24
Novo Nordisk's shares have declined following a warning of reduced sales revenue in the U.S. due to increased competition, particularly from Hims & Hers, which is advertising cheaper alternatives to Wegovy. The company plans to pursue legal action to protect its intellectual property and the integrity of drug approvals, as copycat versions of Wegovy and Ozempic continue to circulate.
Feb 5, 2026
TrumpRx is preparing to launch, but it remains uncertain whether it will reduce medication costs for the majority of patients.
TrumpRx has been launched, but its effectiveness in reducing drug prices for the majority of patients remains uncertain. The initiative aims to address high medication costs, yet questions persist regarding its impact on affordability and accessibility for consumers.
Feb 5, 2026
TrumpRx is preparing to launch, but it remains uncertain whether it will reduce medication costs for the majority of patients - KVIA
The Trump administration launched TrumpRx, a direct-to-consumer drug platform aimed at lowering prescription costs. The site offers discounted medications, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy. While discounts range from 33% to 93%, experts caution that actual savings may vary, and many consumers might still benefit more from insurance coverage.
Feb 5, 2026
Eli Lilly's expansion in the weight-loss market is just beginning, while Novo Nordisk prepares for a downturn in 2026.
Novo Nordisk and Eli Lilly are facing contrasting forecasts in the obesity drug market. While Lilly anticipates a revenue increase to $80-$83 billion in 2026, driven by its drugs Zepbound and Mounjaro, Novo expects a sales decline of 5-13%. Lilly's tirzepatide is seen as superior to Novo's semaglutide, enhancing its market position ahead of the launch of Lilly's oral obesity pill, orforglipron.
Feb 5, 2026
Sales of Ozempic in China decline for the first time as competitors enter the market - Business Day
Novo Nordisk reported a 7% decline in sales of Ozempic injector pens in mainland China, Taiwan, and Hong Kong, totaling approximately 5.4 billion Danish kroner ($853 million) in 2025. The drop is attributed to increased competition from drugs like Eli Lilly's Mounjaro and Innovent Biologics' mazdutide, leading to a potential earnings decrease for the company.
Feb 5, 2026
Cardinal Health raises its yearly profit outlook, driven by increasing demand for specialty medications.
Cardinal Health raised its annual profit expectations after exceeding Wall Street estimates with quarterly revenue of $65.63 billion, driven by strong demand for specialty medicines. The company's pharmaceutical segment generated $60.7 billion, up 19% year-over-year. Analysts remain positive on drug distributors like Cardinal, citing growth potential despite healthcare volatility. Adjusted profit per share reached $2.63, surpassing estimates.
Feb 5, 2026
Novo Nordisk Implements Price Cuts to Broaden Accessibility of Weight-Loss Medications
Novo Nordisk's CEO, Doustdar, announced a price reduction for the weight-loss drug Wegovy, viewing it as an investment to increase access for obesity patients. CFO Karsten Munk Knudsen noted upcoming patent expirations for semaglutide, which may lead to increased competition and a potential 2% sales impact. The company aims for responsible market expansion amid rising competition and safety concerns.
Feb 4, 2026
Novartis Projects 2026 Earnings: Effects of Patent Expirations | GBAF - Global Banking & Finance Review
Novartis anticipates its first annual profit decline in a decade for 2026, primarily due to patent expirations of key drugs like Entresto and Xolair. Despite this, CEO Vas Narasimhan remains optimistic about long-term growth, citing cancer drugs Kisqali and Scemblix as potential offsets. Novartis shares fell 1.8% following the announcement.
Feb 4, 2026
[Why&Next] Biotech Industry Confronts a 580 Trillion Won "Patent Cliff," with SC Conversion as a Crucial Survival Strategy
Celltrion and Alteogen are adopting contrasting strategies in the competitive subcutaneous (SC) formulation market, projected to reach 80 trillion won by 2030. Celltrion targets big pharma directly with its own biosimilars, while Alteogen supports big pharma by supplying its hyaluronidase platform, exemplified by MSD's Keytruda SC. The global market is set to grow significantly as patents expire.
Feb 4, 2026
Senate Democrats Uncover Trump's Recent 'Deception' and Present Strategy to Lower Prescription Drug Prices
Democratic senators, led by Ron Wyden, criticized President Trump's failure to lower prescription drug prices, accusing him of allowing Big Pharma to profit without commitments to affordability. They plan to develop policies for Medicare price negotiations and eliminate abuses in the drug supply chain. The senators emphasized their commitment to reducing costs for American families and ensuring access to lifesaving medications.
Feb 4, 2026
Cortez Masto, Wyden, and their colleagues unveil initiatives to broaden future drug pricing strategies.
U.S. Senators Catherine Cortez Masto, Ron Wyden, Peter Welch, and Ruben Gallego unveiled a plan to lower prescription drug costs, allowing Medicare to negotiate prices more effectively. This initiative aims to alleviate financial burdens on Americans, particularly seniors. The plan follows recent price hikes on drugs like Opdivo, which were exempted from negotiations.
Feb 4, 2026
Europe update: Eli Lilly reports impressive Q4 results, FTSE 100 reaches all-time high, UK economy shows signs of improvement.
Eli Lilly reported stronger-than-expected Q4 earnings, driven by high demand for its obesity drug Zepbound and diabetes treatment Mounjaro, prompting an optimistic outlook for 2026. Meanwhile, London's FTSE 100 reached record highs, buoyed by energy stocks and M&A activity, despite ongoing geopolitical tensions and mixed economic signals in the UK.
Feb 4, 2026
Eli Lilly's expansion in the GLP-1 market is just beginning, while Novo Nordisk prepares for a downturn in 2026.
Eli Lilly and Novo Nordisk are facing contrasting forecasts in the obesity drug market. Lilly anticipates 2026 sales of $80-$83 billion, driven by its effective drugs like Zepbound and Mounjaro, while Novo expects a 5%-13% sales decline. Analysts highlight Lilly's superior drug effectiveness and market share growth, particularly with its upcoming obesity pill, orforglipron, set to compete with Novo's Wegovy.
Feb 4, 2026
For Users of GLP-1, Commitment May Be Crucial for Sustained Health - Athletech News
New data from Noom indicates that engagement in healthy habits significantly enhances the effectiveness of GLP-1 weight-loss drugs like Ozempic and Wegovy. Users who actively interacted with the Noom app lost 25.2% more weight and stayed on medication longer. CEO Geoff Cook emphasizes the importance of behavior change alongside medication for sustained weight loss and overall wellness.
Feb 4, 2026
Eli Lilly Surpasses $1 Trillion Market Value Following Strong Earnings Report - Grand Pinnacle Tribune
Eli Lilly's shares surged over 9% on February 4, 2026, after reporting Q4 earnings that exceeded expectations and issuing a bullish 2026 revenue forecast of $80-$83 billion. The company's blockbuster drugs, Mounjaro and Zepbound, generated $7.41 billion and $4.2 billion in revenue, respectively, boosting its market share in the U.S. obesity and diabetes market to 60.5%.
Feb 4, 2026
Novartis Exceeds Q4 Earnings Expectations, Faces Sales Challenges from Entresto Generics - TradingView
Novartis AG reported fourth-quarter core earnings per share of $2.03, surpassing estimates, while revenues of $13.3 billion fell short. Key drugs like Kisqali and Cosentyx showed strong sales growth, but Entresto and Promacta faced declines due to generic competition. Novartis plans to acquire Avidity Biosciences to enhance its neuroscience pipeline, with a focus on growth drivers amid upcoming patent expirations.
Feb 4, 2026
Novartis warns of a decline in profits by 2026 due to the expiration of patents for important medications - ET Pharma
Novartis anticipates its first annual drop in operating profit in a decade, projecting a low single-digit percentage decline for 2026. The company aims to offset patent expiries of key drugs like Entresto and Xolair with cancer treatments Kisqali and Scemblix. CEO Vas Narasimhan remains optimistic about mid-term growth despite competition from generics.
Feb 4, 2026
Eli Lilly Reaches the Trillion Dollar Mark Once More - Grand Pinnacle Tribune
Eli Lilly has surpassed a $1 trillion market capitalization, driven by a 43% revenue growth to $19.3 billion in Q4 2025, largely from its diabetes and obesity drugs, Mounjaro and Zepbound. The company projects 2026 revenues between $80 billion and $83 billion, bolstered by Medicare coverage expansion and a new GLP-1 obesity pill launch.
Feb 4, 2026
Eli Lilly surpasses profit expectations and raises forecast due to strong sales of Zepbound and Mounjaro.
Eli Lilly reported a strong fourth-quarter performance with net income of $6.64 billion, driven by soaring sales of its GLP-1 drugs, Mounjaro and Zepbound. The company forecasts 2026 revenue between $80 billion and $83 billion, despite potential pricing pressures. Lilly is also set to launch a new oral weight-loss drug, orforglipron, amid intensifying competition from rivals like Novo Nordisk.
Feb 4, 2026
Novo Nordisk predicts that the expiration of patents will impact semaglutide sales in Canada - Global News
Novo Nordisk anticipates a decline in sales due to the expiration of patents for its semaglutide GLP-1 treatments, including Wegovy and Ozempic, in Canada. The company expects increased competition from generics, impacting its market share. Meanwhile, the uptake of its semaglutide pill, Rybelsus, shows promise. Eli Lilly, developing Zepbound and Mounjaro, forecasts a 25% revenue increase for 2026.
Feb 4, 2026
Novo Nordisk predicts that Canada will experience a decline in semaglutide sales as patent protections come to an end - National | Globalnews.ca
Novo Nordisk anticipates a decline in sales due to the expiration of patents for its semaglutide GLP-1 treatments, including Wegovy and Ozempic, in Canada. The company expects increased competition from generics, impacting its market share. Meanwhile, the semaglutide pill, Rybelsus, has shown promising early uptake. Eli Lilly, developing competing GLP-1 drugs, forecasts a 25% revenue increase for 2026.
Feb 4, 2026
Biopharma Shakti: India aims to reduce reliance on China amid patent expiration - The Economic Times
India is set to enhance its biopharmaceutical manufacturing to reduce dependence on China for essential drug components. The initiative aims to leverage upcoming patent expirations of major global drugs, positioning India as a hub for biosimilars and emerging biologics, thereby strengthening its pharmaceutical industry internationally.
Feb 4, 2026
Sales of weight-loss medications in South Africa increase as global lawsuits escalate - Juta MedicalBrief
Sales of weight-loss drugs, particularly Ozempic and Mounjaro, are surging in South Africa, despite rising complaints about severe side effects. A class action suit involving 4,400 patients has been filed against manufacturers like Novo Nordisk and Eli Lilly, citing issues such as gastroparesis and pancreatitis. Medical schemes face challenges in covering these costly treatments, limiting access for many patients.
Feb 4, 2026
Authorities Crack Down on Codeine Syrups, Narcotic Injections, and Controlled Capsules in Response to Increasing Concerns...
Authorities in northern and central India have intensified crackdowns on illicit drug trafficking, resulting in significant seizures of codeine syrups, narcotics injections, and restricted capsules. These actions come amid rising concerns over the misuse of habit-forming substances, as law enforcement aims to combat the growing networks involved in drug smuggling.
Feb 4, 2026
South Africa: Sales of Popular Weight-Loss and Diabetes Medications Rise Despite Financial Obstacles
Sales of weight loss medications Ozempic (semaglutide) and Mounjaro (tirzepatide) have surged in South Africa, despite high costs limiting access. Ozempic, launched by Novo Nordisk, has risen dramatically in spending rankings, while Mounjaro, marketed by Aspen Pharmacare, has become the top pharmaceutical product. Generic versions of semaglutide may be available by 2027, potentially improving access.
Feb 4, 2026
Uttarakhand STF Arrests Major Suspect in Counterfeit Medicine Operation, Confiscates Fake Drugs ...
Uttarakhand STF has arrested Mohan Vaidh, a key figure in a fake medicines network, during a crackdown in Dehradun. The operation resulted in the seizure of counterfeit drug packaging materials used for life-saving drugs, highlighting the ongoing battle against pharmaceutical fraud in the region.
Feb 4, 2026
Wegovy manufacturer cautions about 'difficult' price reductions as stock values drop - BBC
Feb 4, 2026
Merck Braces for Keytruda Patent Expiration — Here's Its Strategy - Stocktwits
Scotiabank has raised its price target for Merck & Co. to $136, maintaining an 'Outperform' rating, following a modest Q4 earnings beat with adjusted EPS of $2.04 and revenue of $16.4 billion. Merck is preparing for a 2028 patent cliff for its cancer drug Keytruda while highlighting $70 billion in potential commercial opportunities by the mid-2030s.
Feb 4, 2026
GSK anticipates a decline in sales growth in 2026 due to impending patent expirations - Vox Markets
GSK Plc anticipates slower turnover growth of 3-5% this financial year, impacted by the expiration of an HIV drug patent and U.S. price reduction policies. New CEO Luke Miels aims for over £40bn in sales by 2031. Shares rose 4% to over £20, with a dividend increase to 70p. The company reported a 4% turnover rise to £32.6bn in 2025.
Feb 4, 2026
Novartis faces significant challenges due to patent expirations, but the CEO has a strategy in place - pharmaphorum
Novartis faces a challenging period as it anticipates significant sales declines due to the loss of patent exclusivity for key drugs, including Entresto (sacubitril/valsartan), Tasigna (nilotinib), and Promacta/Revolade (eltrombopag). CEO Vas Narasimhan remains optimistic about growth from brands like Kisqali (ribociclib) and Kesimpta (ofatumumab), alongside a robust pipeline and upcoming regulatory approvals.
Feb 4, 2026
Government reports in the Rajya Sabha indicate that reliance on API imports is still significant, with China accounting for almost 73.71% of the supply.
India's reliance on imported Active Pharmaceutical Ingredients (APIs) remains high, with China supplying nearly 73.71% of these essential components, according to Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a recent Rajya Sabha reply. This highlights ongoing concerns about the country's dependency on foreign sources for bulk drugs and intermediates.
Feb 4, 2026
GSK anticipates slower sales growth in 2026 as new CEO Miels plans to shift strategy.
GSK's new CEO Luke Miels aims to boost sales growth and expedite new medicine development, targeting over £40 billion in sales by 2031. Following a $2.2 billion acquisition of RAPT Therapeutics, GSK expects 3-5% revenue growth this year, despite challenges in its vaccine business. Shares rose 5.6% to 2,055 pence, marking a 25-year high.
Feb 4, 2026
Novartis warns of a decline in profits by 2026 due to the expiration of patents for important medications.
Novartis forecasts its first annual drop in operating profit in a decade, projecting a low single-digit decline for 2026, impacted by patent expiries of drugs like Entresto and Xolair. The company aims to offset losses with cancer drugs Kisqali and Scemblix, and remains optimistic about mid-term growth despite competition from generics. Shares fell 1.8% following the announcement.
Feb 4, 2026
GSK's Strategic Transition: Managing Expansion in the Face of Patent Issues | Business - Devdiscourse
GSK projected a slowdown in sales growth for 2026 but remains focused on long-term goals, enhancing its treatment pipeline amid patent expirations on key HIV therapies. CEO Luke Miels emphasized challenges from increased research investments while targeting over 40 billion pounds in annual sales by 2031. GSK shares initially dipped but later surged to 1,990 pence, marking a two-decade high.
Feb 4, 2026
How Merck Is Getting Ready for the Patent Expiration of Its Successful Cancer Treatment Keytruda
Scotiabank has raised its price target for Merck & Co. to $136, maintaining an 'Outperform' rating, following a modest Q4 earnings beat with adjusted EPS of $2.04 and revenue of $16.4 billion. Merck is preparing for a 2028 patent cliff for its cancer drug Keytruda while highlighting $70 billion in potential commercial opportunities by the mid-2030s.
Feb 3, 2026
Merck Confronts Upcoming Obstacles Despite Present Achievements | Health - Devdiscourse
Merck & Co. forecasts lower-than-expected 2026 sales and profits due to patent expirations on drugs like Januvia, despite a strong Q4 report boosted by Keytruda, which generated $8.37 billion in sales. Shares fell 1.2% in premarket trading. CEO Rob Davis remains optimistic about the company's strategy, including recent acquisitions of Cidara Therapeutics and Verona Pharma.
Feb 3, 2026
Struggle for affordable HIV medications: Remarkable tales from an individual in India and another in South Africa.
The article highlights the struggle for affordable healthcare against the backdrop of high pharmaceutical prices, particularly in the context of HIV/AIDS treatment. Activist Zackie Achmat led protests in South Africa demanding access to life-saving drugs, while Indian pharmaceutical company Cipla, under Yusuf Hamied, offered affordable AIDS medications, significantly reducing costs and inspiring global health movements.
Feb 3, 2026
Merck exceeds quarterly projections and provides conservative guidance for 2026 amid impending generic competition.
Merck reported fourth-quarter earnings of $2.09 per share and revenue of $16.4 billion, exceeding estimates due to strong demand for Keytruda. However, the company provided a modest 2026 outlook, anticipating revenue between $65.5 billion and $67 billion, below analyst expectations. Merck faces upcoming patent expirations for drugs like Januvia and Janumet, which may pressure sales.
Feb 3, 2026
Concept Medical's Manufacturing Expertise: Sirolimus Coated Balloon - OC Academy
Concept Medical Group has been recognized as one of India’s Top 30 Best Workplaces™ in Manufacturing 2026, highlighting its commitment to a high-trust workplace culture. The company is known for its MagicTouch™ Sirolimus Coated Balloon (SCB), a pioneering device in vascular care, supported by extensive clinical trials. Its manufacturing facility in India produces over one million devices annually, ensuring high-quality medical technology.
Feb 3, 2026
Merck projects 2026 revenue to fall short of expectations due to patent expirations - The Globe and Mail
Merck & Co. forecasted 2026 sales and profits below Wall Street estimates, primarily due to the loss of patent exclusivity on diabetes drug Januvia and related medicines. Despite a strong fourth quarter driven by Keytruda, shares fell 1.2%. Merck expects 2026 revenue of $65.5-$67 billion, below analysts' average estimate of $67.6 billion.
Feb 3, 2026
Duty-free but still unaffordable: The reason behind a 'waived' cancer medication priced at Rs 1 crore - India Today
AstraZeneca's Enhertu (trastuzumab deruxtecan) offers hope for advanced breast cancer patients but comes at a high cost, ranging from Rs 50 lakh to over Rs 1 crore annually. Despite a customs duty exemption in Budget 2024, prices remain unaffordable for most, with advocates calling for stronger policies to improve access to life-saving medications.
Feb 3, 2026
Pfizer Seeks Expansion Opportunities Despite Obstacles | Technology - Devdiscourse
Pfizer reported fourth-quarter earnings of $17.56 billion, surpassing Wall Street expectations, driven by strong sales of Eliquis and the RSV vaccine Abrysvo. Despite challenges from declining COVID-19 product sales and patent expirations, Pfizer remains optimistic, planning to develop new obesity treatments following its $10 billion acquisition of Metsera, with potential approvals by 2028.
Feb 3, 2026
Merck exceeds Q4 profit forecasts but provides a less optimistic outlook for 2026 - TradingView
Merck reported fourth-quarter earnings and revenue exceeding Wall Street estimates, driven by strong sales of its cancer drug Keytruda, which generated $8.37 billion. However, the company’s 2026 revenue guidance fell short of expectations due to patent expirations and pricing pressures. Merck plans to cut costs by $3 billion by 2027 to offset future revenue losses.
Feb 3, 2026
Pfizer surpasses profit expectations as sales of established medications compensate for decline in COVID-related revenue.
Pfizer reported a sales increase to $17.56 billion, surpassing analyst expectations, driven by strong demand for its blood thinner Eliquis and RSV vaccine Abrysvo. Despite challenges from declining COVID-19 product demand and patent expirations, CEO Albert Bourla emphasized 2026 as a pivotal year for new drug developments, particularly in obesity treatments following the $10 billion acquisition of Metsera.
Feb 3, 2026
Weight-loss medications are leading to an ecological crisis—an innovative water-based approach seeks to address this issue...
A new water-based method for peptide drug synthesis has been developed, replacing toxic organic solvents like dimethylformamide (DMF) with water, significantly reducing environmental waste. This breakthrough, involving researchers from the University of Melbourne and SpheriTech Ltd, could transform the production of peptide therapeutics, including GLP-1 receptor agonists like Ozempic, enhancing sustainability in the pharmaceutical industry.
Feb 3, 2026
PharmaTher Aims for Early Involvement in Canada's Growing Generic Semaglutide Sector
PharmaTher Holdings Ltd. has announced plans to seek Health Canada approval for a generic version of semaglutide, the active ingredient in Ozempic and Wegovy, aiming to enter the Canadian market post-regulatory exclusivity. The company, known for its FDA-approved ketamine, targets a cost-effective manufacturing strategy to supply the growing GLP-1 market. Current analyst ratings suggest a Sell for TSE:PHRM stock.
Feb 3, 2026
FDA introduces 'PreCheck' initiative; AstraZeneca and Acadia face delays with their medications - BioPharma Dive
The FDA has launched the "PreCheck" initiative to expedite U.S. drug manufacturing. AstraZeneca's request for a subcutaneous version of lupus drug Saphnelo was rejected, while its cancer drug Datroway received priority review. Acadia Pharmaceuticals faces a negative trend vote for Rett syndrome drug trofinetide in Europe. MeiraGTx partners with ZipBio to develop gene therapy for geographic atrophy.
Feb 3, 2026
Pfizer Unveils Preliminary Obesity Results Indicating Weight Loss of Up to 12.3% - TradingView
Pfizer Inc. reported early data from its newly acquired obesity treatment, showing weight loss of up to 12.3% at 28 weeks. This follows Pfizer's $10 billion acquisition of Metsera Inc. However, shares fell 2.1% amid concerns over efficacy and competition from Novo Nordisk and Eli Lilly. Pfizer also reported strong fourth-quarter sales, despite declining Covid-related revenue.
Feb 3, 2026
NPPA sets retail prices for 36 newly introduced medications, according to DrugsControl Media Services.
The National Pharmaceutical Pricing Authority (NPPA) has set the retail prices for 37 new drugs, including hypertensive and anti-diabetic medications, in accordance with the Drugs Prices Control Order (DPCO), 2013. This decision was made during a recent meeting held in New Delhi.
Feb 3, 2026
Police in India confiscate controlled prescription medications as diversion networks expand...
Police in India have seized regulated prescription drugs, particularly codeine-based medications, amid rising concerns over drug diversion and addiction. Recent operations have led to multiple arrests across various states, underscoring the challenges of cross-border trafficking and the misuse of these substances.
Feb 3, 2026
Merck Faces Profit Challenges as Patent Expiration Approaches | Health - Devdiscourse
Merck & Co has issued a cautious forecast for 2026, predicting revenue shortfalls due to patent expirations for key drugs like Januvia. Despite a strong fourth quarter driven by Keytruda, the company is exploring acquisitions in oncology and immunology to address future financial challenges, following recent deals with Cidara Therapeutics and Verona Pharma.
Feb 3, 2026
Merck projects 2026 revenue to fall short of expectations due to patent expirations | WKZO | Everything Kalamazoo
Merck & Co. forecasts 2026 sales and profits below Wall Street estimates, citing the loss of exclusivity for diabetes drug Januvia and other legacy products. Despite a strong fourth quarter driven by Keytruda, Merck anticipates a $2.5 billion impact from generic competition and price negotiations. The company aims for 5% to 8% revenue growth over time, focusing on long-term growth opportunities.
Feb 3, 2026
Union Health Minister Addresses Concerns About Pharmaceutical Quality and Substandard Medications in Rajya Sabha
Union Health Minister addressed the Rajya Sabha on February 3, 2026, discussing issues related to pharmaceutical quality, substandard drugs, fake vaccines, and antibiotic regulation. The Minister emphasized the government's commitment to ensuring drug safety and efficacy in response to growing public concerns.
Feb 2, 2026
Novo's obesity treatment combination achieves success in diabetes study - BioPharma Dive
Novo Nordisk's CagriSema, an experimental combination shot for diabetes and obesity, outperformed Wegovy in a Phase 3 trial, achieving greater blood sugar reduction and weight loss. CagriSema combines semaglutide with cagrilintide and aims for FDA approval. While it shows promise, it still trails Eli Lilly's Zepbound in overall efficacy. Results from a head-to-head trial with Zepbound are anticipated by March.
Feb 2, 2026
FDA Alert: Updates on Sanofi/Regeneron, Merck, REGENXBIO, and Others - BioSpace
REGENXBIO anticipates an FDA decision on its Hunter syndrome gene therapy RGX-121 by February 8, following a delay for additional data review. Merck seeks to expand Keytruda's indications for ovarian cancer, with a decision expected by February 20. Vanda Pharmaceuticals awaits verdict on Bysanti for bipolar I and schizophrenia by February 21, while Taiho proposes Inqovi for leukemia by February 25. Eton's ET-600 for diabetes insipidus and Ascendis Pharma's TransCon CNP for dwarfism also await decisions by February 25 and 28, respectively. BioMarin targets a label expansion for Palynziq by February 28, and Sanofi and Regeneron propose Dupixent for allergic fungal rhinosinusitis, with a decision due the same day.
Feb 2, 2026
Chong Kun Dang Reports Record Earnings Driven by Successful Co-Marketing, While Profit Margins Decline
Chong Kun Dang Pharmaceutical reported record-high revenue of KRW 1.6924 trillion in 2023, driven by co-marketing blockbuster drugs like Wegovy, Prolia, Atozet, and Januvia. However, operating profit fell 19% to KRW 80.5 billion, and net profit declined 30% to KRW 77.8 billion due to rising costs and the absence of a prior-year tax refund.
Feb 2, 2026
GLP-1 medications are driving a fresh surge in healthcare mergers and acquisitions - BenefitsPRO
Pharma deals are evolving, becoming larger and more complex, according to Bain. Companies are increasingly forming manufacturing partnerships to address production bottlenecks and are investing in oral formulations and dual- and triple-agonist therapies to enhance weight loss and blood sugar control.
Feb 2, 2026
Bristol Myers Squibb's confidence in an old medication's potential for Alzheimer's treatment - STAT News
Bristol Myers Squibb is pursuing approval for Cobenfy, a potential treatment for Alzheimer’s-related psychosis, based on a pivotal 1990s clinical trial. The company awaits results from three key studies later this year, aiming to revive the drug's promise. The journey of Cobenfy involved collaboration with Karuna Therapeutics, which innovatively reintroduced the drug after initial setbacks.
Feb 2, 2026
Novo Nordisk's new obesity medication surpasses Wegovy in advanced diabetes study.
Novo Nordisk's experimental weight-loss drug CagriSema demonstrated superior reductions in blood sugar and body weight compared to Wegovy in a late-stage trial involving 2,728 type 2 diabetes patients. CagriSema led to a 14.2% weight loss versus Wegovy's 10.2%. The combination of cagrilintide and semaglutide also resulted in greater blood sugar reduction, positioning CagriSema as a strong competitor to Eli Lilly’s Zepbound.
Feb 1, 2026
Union Budget 2026: Significant Support for Pharmaceuticals, Biologics, and Healthcare Advancements
Finance Minister Nirmala Sitharaman announced a significant boost for India's pharmaceutical, biologics, and healthcare sectors in the Union Budget 2026-27. The package aims to enhance innovation and provide key reliefs to address the growing burden of non-communicable diseases.
Feb 1, 2026
Budget 2026-27: Government reduces customs duties on 17 medications to alleviate financial strain for cancer patients.
In the 2026-27 budget, Finance Minister Nirmala Sitharaman announced customs duty exemptions on 17 cancer drugs, including AbbVie's venetoclax, Eli Lilly's abemaciclib, and Novartis's Mekinist. This initiative aims to enhance access to life-saving treatments for cancer patients. The list also features India's first CAR-T therapy, talycabtagene autoleucel, marketed by ImmunoAct as NexCAR19.
Feb 1, 2026
Study reveals popular weight loss supplement ineffective for reducing belly fat - New York Post
A recent study found that berberine, a popular herbal supplement touted for weight loss, had no significant effect on reducing visceral or liver fat compared to a placebo. Despite claims that it mimics GLP-1 drugs like Ozempic, experts caution that berberine alone won't lead to drastic weight loss and may interact with other medications.
Feb 1, 2026
AstraZeneca lists on the NYSE while investing $15 billion in China - CNBC
AstraZeneca is set to list on the New York Stock Exchange on Monday, following a $15 billion investment plan in China through 2030 and a partnership with CSPC Pharmaceuticals for obesity treatments. The company aims to balance its U.S. market presence while tapping into China's innovation, amidst increasing pricing pressures in the U.S. market.
Feb 1, 2026
Reasons to Consider Pfizer Stock as a Good Investment | The Motley Fool
Pfizer (PFE) faces challenges as it falls behind in the GLP-1 drug market and approaches patent cliffs. Despite a significant stock decline since its COVID-19 vaccine success, the company is pursuing growth by acquiring a promising GLP-1 pipeline and agreeing to distribute a Chinese GLP-1 therapy. Investors are advised to adopt a long-term perspective amid these developments.
Feb 1, 2026
Pfizer Confronts Patent Expiration Issues While Seeking a Recovery | Intellectia.AI
Wall Street analysts predict a rise in Pfizer Inc. (PFE) stock, with a 12-month average price target of $28.56. Cantor Fitzgerald raised its target to $27, while UBS initiated coverage with a $25 target, both maintaining Neutral ratings. Analysts emphasize the importance of upcoming data on obesity treatments and Lyme disease vaccines over quarterly results.
